Volume 11, Number 8, August 2005

Influenza A (H3N2) Outbreak, Nepal

Luke T. Daum,*† Michael W. Shaw,‡ Alexander I. Klimov,‡ Linda C. Canas,* Elizabeth A. Macias,* Debra Niemeyer,* James P. Chambers,† Robert Renthal,† Sanjaya K. Shrestha,§ Ramesh P. Acharya,¶ Shankar P. Huzdar,¶ Nirmal Rimal,¶ Khin S. Myint,# and Philip Gould*
*Air Force Institute for Operational Health, Brooks City Base, San Antonio, Texas; †University of Texas, San Antonio, Texas; ‡Centers for Disease Control and Prevention, Atlanta, Georgia; §Walter Reed/Armed Forces Research Institute of Medical Sciences Research Unit-Nepal, Kathmandu, Nepal; ¶Association of Medical Doctors of Asia-Nepal, Kathmandu, Nepal; and #US Army Medical Component of the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

Figure 3. Three-dimensional top view of the HA1 hemagglutinin structures for A) a representative A/Nepal/1648/04 virus and B) vaccine strain A/Wyoming/3/03. Most (24/26) of the Nepal isolates contain a lysine to asparagine substitution (shown in yellow) at position 145 (K145N). Magenta, residues 226 and 227; orange, residue 189; green, residues 155 and 156; yellow, residue 145. Hemagglutinin molecules were generated by using the respective amino acid sequences with MOLMOL (12). A/Nepal/1648/04 is available from GenBank under accession no. AY945264.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed July 15, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention